← All stories
Health, Longevity & Biohacking

Dr Chris Thompson says Whitehall II links fasting insulin to earlier diabetes risk

By Egleze Editorial Desk · Published September 23, 2026 · Huberman Lab · Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson
Dr Chris Thompson says Whitehall II links fasting insulin to earlier diabetes risk
Huberman Lab
Huberman Lab
Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson

What was said

""They saw that if someone had high fasting insulin, they're more likely to get diabetes long term. So, so and it was a long period of time. It was like a 10 15 year time. They could detect this thing 15 years earlier.""

Dr Chris Thompson cites the Whitehall II study and says higher fasting insulin was linked to later diabetes, detectable 10–15 years in advance. He argues routine care often overlooks fasting insulin and recommends earlier metabolic-risk checks, including limited use of continuous glucose monitors.

Verification status

Attributed speaker claim

Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.

Source and context

Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.

Speaker
Dr. Chris Thompson · guest
Programme
Huberman Lab
Episode
Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson
Clip time
1:08:48
Original source
Watch the source segment →
From this episode
Huberman Lab
Huberman Lab

Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson

September 21, 2026 · 2h 27m · 7 Egleze moments
Read episode summary and key points →

More moments from this episode

Health, Longevity & BiohackingDr Chris Thompson recalls fistula closure after bypass linked to diabetes improvement→Health, Longevity & BiohackingDr Chris Thompson says many patients discontinue GLP-1 drugs within a year→Health, Longevity & BiohackingDr Chris Thompson claims duodenal ablation can cut HbA1c by over a point→Health, Longevity & BiohackingDr Chris Thompson describes patients ‘micro-dosing’ GLP-1s by decanting pen doses into vials→
More stories More from Huberman Lab